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Background: 
Postherpetic neuralgia (PHN) is usually managed pharmacologically. It is not uncommon for patients with 
chronic kidney disease (CKD) to suffer from PHN. It is difficult to prescribe a sufficient dose of anticonvulsants 
for intractable pain because of the decreased glomerular filtration rate. If the neural blockade and pulsed 
radiofrequency ablation provide only short-term amelioration of pain, spinal cord stimulation (SCS) with a low 
l e v e l  o f  e v i d e n c e  m a y  b e  u s e d  o n l y  a s  a  l a s t  r e s o r t .  T h i s  s t u d y  w a s  d o n e  t o  e v a l u a t e  t h e  e f f i c a c y  o f  s p i n a l  
cord stimulation in the treatment of PHN in patients with CKD. 
Methods: 
PH N  p atien ts w ith C KD  w h o  n eeded  h em o -d ialysis w h o r eceived  in sufficien t r elief of p ain  o ver a V A S o f 
8 regardless of the neuropathic medications were eligible for SCS trial. The follow-up period was at least 2 
years after permanent implantation.
Results: 
Eleven patients received percutaneous SCS test trial from Jan 2003 to Dec 2007. Four patients had 
successfully received a permanent SCS implant with their pain being tolerable at a VAS score of less than 
3 along with small doses of neuropathic medications. 
Conclusions: 
SCS was helpful in managing tolerable pain levels in some PHN patients with CKD along with tolerable 
neuropathic medications for over 2 years. (Korean  J  Pain  2011;  24:  154-157)
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INTRODUCTION
　　Postherpetic neuralgia (PHN) is defined as pain per-
sisting for more than 1-6 months after the rash has healed 
[1-3]. Disseminated herpes zoster occurs primarily in im-
munocompromised patients including patients with chronic 
kidney disease (CKD) undergoing a regular schedule of he-
mo-dialysis [4,5]. 
　　Doses of anticonvulsants need to be adjusted in these 
patients  according  to  the  glomerular  filtration  rate  and 
the ir sc hed u l ed dia l y sis [3,6]. Ho w e v er, it is diffic u l t f or 
them to adjust to the doses of neuropathic medications. 
If the neural blockade and pulsed radiofrequency ablation 
provide  only short-term  amelioration  of  pain  [7],  spinal 
cord stimulation (SCS) with a low level of evidence may be 
used only as a last resort.
　　SCS is well known to be effective in some patients with 
failed  back  surgery  syndrome,  peripheral  vascular  dis-
orders,  and  complex  regional  pain  syndrome  [8-11]. 
However, it is rare to find the studies with good results 
in patients with PHN. 
　　The aim of study was to evaluate the efficacy of spinal 
cord stimulation in the treatment of PHN in patients with 
chronic kidney disease.  
MATERIALS  AND  METHODS
　　This retrospective study was done at a pain clinic of 
Pusan National University Hospital in Korea. The recruit-
ment period was from January 2003 to December 2007. 
The pr o toco l w as ap pr o v ed b y th e P o licy of the Ethica l 
Committee at Pusan National University Hospital Institu-
tional Review Board. The patients eligible were informed 
about the procedure of the study and agreed to participate 
in this study and gave their written consent. 
　　The PHN patients with CKD who needed hemo-dialysis 
who received insufficient relief from pain with a visual an-
alogue scale score of over 8 for at least 6 months regard-
less of neuropathic medications were eligible for percuta-
neous SCS test trial. A permanent SCS implant was im-
planted after patients had experienced at least 50% reduc-
tion in the pain score. The follow-up period was at least 
2 years after permanent SCS implantation. The successful 
cases of permanent SCS implantation were defined as the 
patients who had experienced at least 50% reduction in 
pain score continuously with tolerable neuropathic medi-
cations till the end of study.
　　The efficacy of the permanent SCS implant was eval-
uated using the pain score and daily doses of neuropathic 
medications at the final visit day for the successful cases 
of the permanent SCS implants. The complications related 
to SCS were also recorded.
 RESULTS
　　All postherpetic neuralgia pain patients with chronic 
renal failure who had received trial spinal cord stimulation 
were male. Mean age was 66.1 ± 4.5 years old. Mean du-
ration of pain was 24.5 ± 5.2 months. Dermatomal dis-
tributions of pain were 1 cervical, 8 thoracic, and 2 thor-
acolumbar areas. Mean duration after diagnosis of chronic 
renal failure was 8.3 ± 1.8 years. Mean duration of he-
mo-dialysis was 6.6 ± 1.2 years. Their stages of renal 
failure were from 3B to 4. Four patients had comorbid dia-
betes mellitus. All patients had received hemo-dialysis 3 
times a week regularly (T able 1). 
　　Eleven patients received the SCS test trial during the 
study period. Four patients had the permanent SCS im-
planted successfully with their pain being tolerable with a 
VAS score of less than 3 along with small doses of neuro-
pathic medication at the final visit. Mean follow-up period 
was 34.5 months (range, 28 to 41 months) (Table 2). There 
were no complications related to the SCS implant including 
lead migration, infection, or bleeding.  
DISCUSSION
　　Although it was a small number of PHN patients with 
CKD, 4 of the 11 patients showed considerable relief of pain 
and experienced mild pain intensity of less than VAS 3 with 
tolerable neuropathic medications. 
　　It seemed that factors including age, dermatomal dis-
tribution and duration of pain, duration of hemo-dialysis 
and CKD, s tages of CKD, an d com or bi dity bet w een th e 
success or failure group of permanent SCS did not show 
any differences in the effectiveness of SCS in this study. 
Randomized clinical studies showed the efficacy of antiviral 
agents  in  the  prevention  of  PHN  and  the  use  of  anti-
convulsants, antidepressants, opioids, and lidocaine patch 
in the treatment of PHN (level A evidence). The role of epi-
dural local anesthetic and steroid injections in preventing 
PHN has not been completely established (level B evidence). 156 Korean J Pain Vol. 24, No. 3, 2011
Table 1. Baseline Characteristics of Postherpetic Neuralgic Pain Patients With Chronic Renal Failure
Patient Age
Duration of 
pain (m)
Dermatomal 
distribution
Stage of chronic 
kidney disease
Duration of 
hemo-dialysis/CKD (y)
Comorbidity
Permanent spinal 
cord stimulation
1
2
3
4
5
6
7
8
9
10
11
72
67
66
58
69
68
63
59
66
68
71
35
28
18
26
21
31
22
19
21
23
26
Rt. T4-T6
Lt. T3-T6
Lt. T10-L1
Rt. C5-C7
Lt. T4-T7
Rt. T4-T7
Rt. T3-T6
Lt. T12-L2
Rt. T4-T6
Rt. T4-T7
Lt. T5-T7
3B
4
3B
4
4
4
4
4
4
3B
3B
5/8
 7/10
8/8
6/9
7/8
7/7
 8/10
7/9
 8/11
5/6
5/5
1
2
−
1
3
1
−
1
−
−
2
＋
＋
＋
＋
−
−
−
−
−
−
−
Stage of chronic kidney disease (CKD): Stage 1-kidney damage with normal or increased GFR (GFR ≥ 90 ml/min/1.73 m
2); Stage 2-kidney
damage with mild reduction in GFR (GFR = 60−89 ml/min/1.73 m
2); Stage 3-Moderate reduction in GFR (Stage 3A: GFR = 45−59
ml/min/1.73 m
2, Stage 3B: GFR = 30−44 ml/min/1.73 m
2); Stage 4-Severe reduction in GFR (GFR = 15−29 ml/min/1.73 m
2); Stage
5-kidney failure (GFR = 15 ml/min/1.73 m
2) [modified from http://www.nice.org.uk/nicemedia/live/12069/42116/42116.pdf].
Comorbidity: 1. diabetes mellitus, 2. hypertension, 3. cerebrovascular disorders. GFR: glomerular filtration rate.
Table 2. Successful 4 Cases of Permanent Spinal Cord Stimulation (SCS) Implantation
Patient
Follow-up period after 
permanent SCS 
implantation (m)
Neuropathic medications at final visit day
VAS score at 
final visit day
1
2
3
4
28
41
38
31
Nortriptyline 12.5 mg qd
Nortriptyline 12.5 mg qd
Nortriptyline 12.5 mg qd
Gabapentin 100 mg t.i.d
Gabapentin 100 mg qd
Gabapentin 100 mg b.i.d
Gabapentin 100 mg qd
Tramadol 100 mg qd
Tramadol 100 mg qd
2.5
2.9
1.5
1.8
VAS: visual analogue scale ranging from 0 to 10, with being no pain at all and 10 being the worst pain imaginable.
Intrathecal steroid injections and topical capsaicin may be 
e f f e c t i v e  i n  P H N  ( l e v e l  B  e v i d e n c e ) .  A  n o n - r a n d o m i z e d  
controlled  study  supports  the  usefulness  of  spinal  cord 
stimulation [3,12]. SCS is considered to be of poor value 
in treating PHN because of deafferentation and scarring 
of the dorsal horn and dorsal root ganglion. A retrospective 
stud y f or SCS f or pain con tr o l of 30 perip her al neur o-
pathies revealed that causalgic and diabetic neuropathic 
pain seem to respond relatively well, whereas postherpetic 
pain and intercostal neuralgia syndromes seem to respond 
less favorably to the long-term beneficial effects of SCS 
[13]. 
　　However, Harke et al. [14] insisted that SCS treatment 
of PHN may offer a worthwhile option in the treatment of 
pharmacological  nonresponders  with  anatomically  intact 
neural pathways, provided the patients accept such an in-
v a s i v e  a p p r o a c h .  I n  c a s e s  o f  u n b e a r a b l e  h e r p e s  z o s t e r  
pain, this approach may have supportive benefit as well. 
Iseki et al. [15] reported that excellent outcomes were ach-
ieved with SCS for 7 to 10 days on 2 patients who developed 
PHN within 2 to 3 months of the onset of the condition. 
They believed that limited-duration SCS for subacute PHN 
is a useful treatment approach that may prevent pain from 
progressing to chronic PHN. The other positive result of 
SCS in the treatment of PHN was introduced by Meglio et 
al. in 1989. Although positive in only 6 of the 10 patients, 
the effectiveness of SCS was remarkably stable over time. 
T h e y  t h e r e f o r e  r e c o m m e n d  a  p e r c u t a n e o u s  t e s t  t r i a l  o f 
SCS in every case of PHN resistant to medical treatment 
[16]. The efficacy of peripheral subcutaneous stimulation 
f o r  t h e  t r e a t m e n t  o f  i n t r a c t a b l e  P H N  w a s  r e c e n t l y  i n-
troduced [17,18]. However, because the main pathogno- I Y  B e a k,  e t  a l  /  S C S  f o r  P H N  i n  P a t i e n t s  w i t h  C K D 157
monic lesion is known to be the dorsal horn, it is better 
to believe its role to be in partial control of the origin of 
the pain. The basic pain mechanism of PHN is known to 
originate  from  both  the  central  and  peripheral  nervous 
systems. The central mechanism is a disinhibition of the 
large afferent (Aβ) fibers, central reorganization, and cen-
tral  sensitization.  The  peripheral  mechanism  is  ectopic 
discharge,  increased  sympathetic activity  and  catechol-
amines on the sensitized and damaged primary afferents, 
and  continuous  inflammatory  response  of  the  sensory 
nerve or nervi nervorum [19].   
　　The great limitation of this study was the small num-
ber of patients. A well-designed comparative prospective 
multi-center studies are needed. The other limitation is the 
control ability of the SCS instrument because of old age. 
Only the patients know characteristics and intensity of the 
pain; however, they will not or cannot manipulate the mode 
of the SCS. It is difficult to use the SCS even with the best 
mode  of  control.  Therefore,  SCS  in  the  elderly  may  be 
underestimated. It is also difficult to perform SCS trial test 
for pain in the subacute stage of PHN due to insurance 
coverage. 
　　SCS was helpful in managing with tolerable pain levels 
in some PHN patients with CKD along with tolerable neu-
ropathic medications for over 2 years.
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